Loading
Life sciences · Journal article
Journal of Experimental & Clinical Cancer Research · October 7, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Beyond its canonical roles in bone mineralization and extracellular matrix remodeling, secreted phosphoprotein 1 (SPP1) has emerged as a central regulator of the tumor microenvironment (TME), orchestrating immunosuppressive programs that drive immune evasion and tumor progression. Produced by tumor cells, tumor-associated macrophages (TAMs), and cancer-associated fibroblasts, SPP1 signals through integrins and CD44 variants to promote pro-tumor macrophage polarization, impair innate immune cell function, induce T cell exclusion and exhaustion, and remodel the extracellular matrix to reinforce immune exclusion. Growing evidence has identified the SPP1 axis as a promising therapeutic target, leading to the development of strategies including SPP1 neutralization, receptor blockade, depletion or reprogramming of SPP1⁺ TAMs, and combination therapies with immune checkpoint inhibitors, STING agonists, cytokine-based therapies, radiotherapy, and chemotherapy. This review summarizes the molecular and cellular mechanisms by which SPP1 shapes the tumor immune landscape, highlights emerging therapeutic approaches targeting the SPP1 axis, and discusses key translational challenges, including the context-dependent nature of SPP1 signaling, biomarker development, and patient stratification. Targeting the SPP1 axis offers a promising strategy for remodeling the TME and enhancing antitumor immunity.